Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to investigate the monoaminergic
(dopamine、serotonin、and norepinephrine ) nervous system and amyloid deposition in Parkinson's
disease patients with non-motor symptoms (focus on impulse control disorders and dementia) by
novel 18F-DTBZ and Florbetapir F-18 PET imaging.
This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and
monoaminergic function by18F- DTBZ PET in NC group, PD group, PDD group, AD group.
Investigators will also analyze monoaminergic function by18F- DTBZ PET in PDI group.